Is SVRA or SYRE more undervalued in 2026?

CirclFi compares Savara, Inc. (SVRA) and Spyre Therapeutics, Inc. (SYRE) using 13 institutional-grade valuation models. SVRA has a Quality of Company score of 4.5/10 while SYRE scores 5.4/10.

Which is a better buy — SVRA or SYRE?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do SVRA and SYRE valuations compare?

SVRA at $5.09 and SYRE at $72.11 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

SVRA vs SYRE Valuation Comparison 2026 — Intrinsic Value Analysis

SVRA

Biotechnology

Savara, Inc.

Quality

4.5

out of 10

Value Trap

LOW

Price

$5.09

Last close

Models

7/13

Active

SYRE

Biotechnology

Spyre Therapeutics, Inc.

Quality

5.4

out of 10

Value Trap

SAFE

Price

$72.11

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	SVRA Fair Value	SVRA Upside	SYRE Fair Value	SYRE Upside
Bayesian DCF	Intrinsic	$1.41	-72.2%	$22.23	-69.2%
Earnings Power Value	Intrinsic	—	—	$30.32	-56.5%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.40	-92.2%	$2.02	-97.3%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for SVRA vs SYRE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SVRA vs SYRE — Which Stock Is More Undervalued?

SYRE scores higher with a 5.4/10 quality rating vs SVRA's 4.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Savara, Inc. (SVRA) and Spyre Therapeutics, Inc. (SYRE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SVRA currently trades at $5.09 with a QOC of 4.5/10, while SYRE trades at $72.11 with a QOC of 5.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).